Mixed connective tissue disease medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 12: | Line 12: | ||
** Rate of progression | ** Rate of progression | ||
* Treatment strategies must follow conventional therapies that are used for similar problems in other [[Rheumatology|rheumatic]] diseases ([[systemic lupus erythematosus]], [[scleroderma]], [[polymyositis]]).<ref name="pmid16084325">{{cite journal |vauthors=Kim P, Grossman JM |title=Treatment of mixed connective tissue disease |journal=Rheum. Dis. Clin. North Am. |volume=31 |issue=3 |pages=549–65, viii |date=August 2005 |pmid=16084325 |doi=10.1016/j.rdc.2005.04.008 |url=}}</ref> | * Treatment strategies must follow conventional therapies that are used for similar problems in other [[Rheumatology|rheumatic]] diseases ([[systemic lupus erythematosus]], [[scleroderma]], [[polymyositis]]).<ref name="pmid16084325">{{cite journal |vauthors=Kim P, Grossman JM |title=Treatment of mixed connective tissue disease |journal=Rheum. Dis. Clin. North Am. |volume=31 |issue=3 |pages=549–65, viii |date=August 2005 |pmid=16084325 |doi=10.1016/j.rdc.2005.04.008 |url=}}</ref> | ||
** For more information about treatment of [[systemic lupus erythematosus]] click '''here'''. | |||
** For more information about treatment of [[scleroderma]] click '''here'''. | |||
** For more information about treatment of [[Polymyositis and dermatomyositis|polymyositis]] click '''here'''. | |||
* Patients usually react to low doses of [[Steroid|steroids]] and [[Non-steroidal anti-inflammatory drug|non-steroidal anti-inflammatory drugs]], in combination with [[Immunosuppressive drug|immunosuppressive drugs]] or [[Biology|biologic]] agents ([[monoclonal antibodies]]).<ref name="pmid24353496">{{cite journal |vauthors=Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E |title=Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl |journal=Postepy Dermatol Alergol |volume=30 |issue=5 |pages=329–36 |date=October 2013 |pmid=24353496 |pmc=3858664 |doi=10.5114/pdia.2013.38365 |url=}}</ref> | * Patients usually react to low doses of [[Steroid|steroids]] and [[Non-steroidal anti-inflammatory drug|non-steroidal anti-inflammatory drugs]], in combination with [[Immunosuppressive drug|immunosuppressive drugs]] or [[Biology|biologic]] agents ([[monoclonal antibodies]]).<ref name="pmid24353496">{{cite journal |vauthors=Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E |title=Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl |journal=Postepy Dermatol Alergol |volume=30 |issue=5 |pages=329–36 |date=October 2013 |pmid=24353496 |pmc=3858664 |doi=10.5114/pdia.2013.38365 |url=}}</ref> | ||
* In [[refractory]] cases or in severe clinical conditions, [[Antibody|immunoglobulins]], [[Chemotherapy|cytotoxic agents]] (such as [[cyclophosphamide]]) or [[Biology|biologic]] drugs can be administered.<ref name="pmid243534962">{{cite journal |vauthors=Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E |title=Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl |journal=Postepy Dermatol Alergol |volume=30 |issue=5 |pages=329–36 |date=October 2013 |pmid=24353496 |pmc=3858664 |doi=10.5114/pdia.2013.38365 |url=}}</ref> | * In [[refractory]] cases or in severe clinical conditions, [[Antibody|immunoglobulins]], [[Chemotherapy|cytotoxic agents]] (such as [[cyclophosphamide]]) or [[Biology|biologic]] drugs can be administered.<ref name="pmid243534962">{{cite journal |vauthors=Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E |title=Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl |journal=Postepy Dermatol Alergol |volume=30 |issue=5 |pages=329–36 |date=October 2013 |pmid=24353496 |pmc=3858664 |doi=10.5114/pdia.2013.38365 |url=}}</ref> | ||
Revision as of 15:26, 18 April 2018
|
Mixed connective tissue disease Microchapters |
|
Differentiating Mixed connective tissue disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Mixed connective tissue disease medical therapy On the Web |
|
American Roentgen Ray Society Images of Mixed connective tissue disease medical therapy |
|
Directions to Hospitals Treating Mixed connective tissue disease |
|
Risk calculators and risk factors for Mixed connective tissue disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
Medical Therapy
- The treatment of patients with MCTD is organ specific and depends on:[1]
- Kind of internal organ involvement
- Phase of the disease
- Rate of progression
- Treatment strategies must follow conventional therapies that are used for similar problems in other rheumatic diseases (systemic lupus erythematosus, scleroderma, polymyositis).[2]
- For more information about treatment of systemic lupus erythematosus click here.
- For more information about treatment of scleroderma click here.
- For more information about treatment of polymyositis click here.
- Patients usually react to low doses of steroids and non-steroidal anti-inflammatory drugs, in combination with immunosuppressive drugs or biologic agents (monoclonal antibodies).[1]
- In refractory cases or in severe clinical conditions, immunoglobulins, cytotoxic agents (such as cyclophosphamide) or biologic drugs can be administered.[3]
- Plasmapheresis may be a therapeutic option, especially when it is combined with agents that can block production of pathogenic autoantibodies, such as rituximab (a monoclonal antibody anti-CD20 which can modulate the disease activity).
References
- ↑ 1.0 1.1 Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E (October 2013). "Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl". Postepy Dermatol Alergol. 30 (5): 329–36. doi:10.5114/pdia.2013.38365. PMC 3858664. PMID 24353496.
- ↑ Kim P, Grossman JM (August 2005). "Treatment of mixed connective tissue disease". Rheum. Dis. Clin. North Am. 31 (3): 549–65, viii. doi:10.1016/j.rdc.2005.04.008. PMID 16084325.
- ↑ Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E (October 2013). "Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl". Postepy Dermatol Alergol. 30 (5): 329–36. doi:10.5114/pdia.2013.38365. PMC 3858664. PMID 24353496.